News
HAE
90.49
-0.94%
-0.86
Haemonetics (HAE) Q1 2027 Earnings Call Transcript
The Motley Fool · 8h ago
Haemonetics (HAE) Receives a Hold from Citi
TipRanks · 9h ago
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
NASDAQ · 11h ago
Mizuho Securities Reaffirms Their Buy Rating on Haemonetics (HAE)
TipRanks · 1d ago
Haemonetics (HAE) Gets a Buy from Bank of America Securities
TipRanks · 1d ago
Does Strong Q1 Results And VASCADE Data Shift The Bull Case For Haemonetics (HAE)?
Simply Wall St · 1d ago
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know
NASDAQ · 2d ago
J.P. Morgan Sticks to Its Hold Rating for Haemonetics (HAE)
TipRanks · 2d ago
Weekly Report: what happened at HAE last week (0803-0807)?
Weekly Report · 3d ago
Haemonetics Lifts Outlook on Broad-Based Earnings Strength
TipRanks · 3d ago
Is Haemonetics (HAE) Undervalued As Q1 Earnings And Outlook Lift Optimism?
Simply Wall St · 4d ago
Haemonetics (HAE) Stock Extends Run As Cash Flow Strength Meets Margin Pressure
Simply Wall St · 5d ago
Haemonetics Is Maintained at Neutral by Citigroup
Dow Jones · 5d ago
Haemonetics Price Target Raised to $92.00/Share From $79.00 by Citigroup
Dow Jones · 5d ago
Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $92
Benzinga · 5d ago
Haemonetics Is Maintained at Neutral by JP Morgan
Dow Jones · 6d ago
Haemonetics Price Target Raised to $86.00/Share From $62.00 by JP Morgan
Dow Jones · 6d ago
JP Morgan Maintains Neutral on Haemonetics, Raises Price Target to $86
Benzinga · 6d ago
Haemonetics price target raised to $105 from $90 at Raymond James
TipRanks · 6d ago
Haemonetics price target raised to $96 from $88 at Baird
TipRanks · 6d ago
More
Webull provides a variety of real-time HAE stock news. You can receive the latest news about Haemonetics Corp Mass through multiple platforms. This information may help you make smarter investment decisions.
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.